Novo Nordisk launches anti-diabetes pill semaglutide in India | Boulder Peptide Symposium

September 15-18, 2025

LIVE, In Person at the St. Julien Hotel in Boulder, Colorado
The only conference focused solely on the pharmaceutical development of peptide therapeutics.

Novo Nordisk launches anti-diabetes pill semaglutide in India

Novo Nordisk launches anti-diabetes pill semaglutide in India

Novo Nordisk, the Danish drug maker on Thursday announced the launch of oral semaglutide in India for treatment of type 2 diabetes.

The oral semaglutide will cost Rs 315 per pill or around Rs 10000 for a full month treatment.

"We have kept it at the (similar) price range of the injectable GLP-1, not only that we have followed price equilibrium band, which means if a person goes from 3 mg to 7 mg, the cost they pay is just 9-10% higher, and not double, as per conventional models ..

Read more at:
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/novo-nordisk-launches-anti-diabetes-pill-semaglutide-in-india/articleshow/89024394.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst


s2Member®
loading...